Array Biopharma Inc (ARRY) Director Sells $368,940.00 in Stock

Array Biopharma Inc (NASDAQ:ARRY) Director Lunsen Gil J. Van sold 21,500 shares of Array Biopharma stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $17.16, for a total value of $368,940.00. Following the sale, the director now directly owns 32,797 shares of the company’s stock, valued at $562,796.52. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Shares of Array Biopharma Inc (ARRY) traded up $0.26 during midday trading on Friday, reaching $18.15. The company’s stock had a trading volume of 2,594,375 shares, compared to its average volume of 4,704,370. The firm has a market cap of $3,460.00, a PE ratio of -23.57 and a beta of 2.03. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.17 and a quick ratio of 6.17. Array Biopharma Inc has a 52-week low of $6.73 and a 52-week high of $18.30.

Array Biopharma (NASDAQ:ARRY) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. The firm had revenue of $42.21 million during the quarter, compared to analysts’ expectations of $26.81 million. Array Biopharma had a negative return on equity of 107.79% and a negative net margin of 98.51%. The company’s quarterly revenue was down 5.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.14) EPS. equities research analysts expect that Array Biopharma Inc will post -0.87 earnings per share for the current fiscal year.

Several research firms recently weighed in on ARRY. Stifel Nicolaus lifted their price target on Array Biopharma from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th. SunTrust Banks reissued a “buy” rating and set a $20.00 price target on shares of Array Biopharma in a report on Tuesday, February 6th. BidaskClub cut Array Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, December 2nd. Leerink Swann lifted their price target on Array Biopharma from $19.00 to $20.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Finally, Zacks Investment Research raised Array Biopharma from a “sell” rating to a “hold” rating in a report on Friday, February 9th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $16.43.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Array Biopharma by 70.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,244 shares of the biopharmaceutical company’s stock valued at $118,000 after acquiring an additional 3,834 shares in the last quarter. QS Investors LLC acquired a new position in Array Biopharma in the 4th quarter valued at $134,000. Fox Run Management L.L.C. acquired a new position in Array Biopharma in the 3rd quarter valued at $146,000. Quantitative Systematic Strategies LLC acquired a new position in Array Biopharma in the 4th quarter valued at $169,000. Finally, First Mercantile Trust Co. acquired a new position in Array Biopharma in the 4th quarter valued at $182,000. 94.02% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This story was published by Week Herald and is the property of of Week Herald. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://weekherald.com/2018/02/23/array-biopharma-inc-arry-director-sells-368940-00-in-stock.html.

Array Biopharma Company Profile

Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).

Insider Buying and Selling by Quarter for Array Biopharma (NASDAQ:ARRY)

Receive News & Ratings for Array Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply